Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors
Hua Zhang, Shijia Zhou, Jacek Plewka, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10579-10603
Closed Access | Times Cited: 11

Showing 11 citing articles:

Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Natalie Fuchs, Longfei Zhang, Laura Calvo‐Barreiro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 68-68
Open Access | Times Cited: 8
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 5
Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
Yongling Xu, Huijie Du, Weibo Guo, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 4083-4099
Closed Access | Times Cited: 4
A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
Marialuigia Fantacuzzi, Roberto Paciotti, Mariangela Agamennone
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 316-316
Open Access | Times Cited: 4
Progress in small-molecule inhibitors targeting PD-L1
J. Xu, Yuanfang Kong, Pengbo Zhu, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 4, pp. 1161-1175
Closed Access | Times Cited: 4
Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma
Somaya A. Abdel‐Rahman, Moustafa T. Gabr
Cancers (2024) Vol. 16, Iss. 2, pp. 435-435
Open Access | Times Cited: 3
Design, Synthesis, and Evaluation of 8-(o-Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists
Xingye Wu, He Li, Han Liu, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 4, pp. 518-523
Closed Access | Times Cited: 1
Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction
Chenglong Xu, Zhiqiang Sun, Xuewen Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107376-107376
Closed Access | Times Cited: 1
Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction
Feng Zhang, Qimeng Yu, Caiyun Wu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117867-117867
Closed Access | Times Cited: 1
Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing
Mengmeng Sun, Shixuan Lv, Yanyan Pan, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107874-107874
Closed Access
Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against pd-1/pd-l1
Pujan Sasmal, P. Prabitha, B. R. Prashantha Kumar, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 108036-108036
Closed Access
Page 1

Scroll to top